Want to see FDMT full AI Analyst Report?
FDMT Stock Chart & Stats
$10.49
-$0.14(-2.20%)
At close: 4:00 PM EST
$10.49
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$4.11 - $14.00
Previous CloseN/A
Volume165.32K
Average Volume (3M)736.92K
Market Cap
$664.95M
Enterprise Value$440.49M
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$20.54M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 06, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding52,276,253
10 Day Avg. Volume751,996
30 Day Avg. Volume736,921
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue4.99
Enterprise Value/Gross Profit-40.11
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$30.33Price Target Upside189.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.03
Revenue Forecast (FY)$12.23M
Bulls Say, Bears Say
Bulls Say
Proprietary Engineered AAV Vector Platform4D's engineered AAV platform provides a durable technological moat: tissue-targeted delivery increases potential efficacy and tolerability across indications, raises partner interest, and supports differentiated clinical candidates that can drive long-term licensing, royalty and product opportunities.
Low Leverage And Solid CapitalizationRelative low debt reduces solvency risk during extended clinical development, preserving strategic optionality to raise equity or execute partnerships. A modest debt burden supports runway management and lowers refinance/default risk compared with highly levered biotech peers over the next several quarters.
Ability To Scale Revenue Via PartnershipsThe company demonstrated it can generate meaningful collaboration/license revenue, indicating commercial partner interest and milestone monetization capability. Sustainable partnership revenue potential improves funding optionality and de-risks some development spend compared with firms fully reliant on equity markets.
Bears Say
Sustained Negative Operating Cash FlowLarge, persistent cash burn creates ongoing funding needs and increases likelihood of dilutive financings or reliance on milestone/loan draws. Over a multi-quarter horizon this cash flow profile can constrain R&D pacing, force prioritization of programs, and elevate execution risk absent recurring product revenue.
Deep Operating Losses And Unstable MarginsMaterial and volatile losses indicate the company lacks current earnings power; negative margins and declining equity reflect value erosion. Sustained unprofitability means commercial and regulatory success is required to achieve positive margins, making long-term returns highly binary and development-risk dependent.
Senior Secured Loan With Restrictive CovenantsWhile the facility adds liquidity, senior security and covenants constrain strategic flexibility, limit future collateral availability, and create default risk if milestones or market metrics slip. Covenants can force conservative cash management and affect timing of R&D investments or partnering decisions.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $4.11 and its highest was $14.00 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $664.95M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on May 07, 2026. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.996 by -$0.014.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 52,276,253 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.996. Following the earnings report the stock price went up 2.115%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.33 (189.16% Upside)
$30.33 (189.16% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $117.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.09%
12-Months-Change
Fundamentals
Return on Equity
-36.83%
Trailing 12-Months
Asset Growth
-0.55%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$30.33
▲(189.16% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
2.18% Insiders
13.18% Mutual Funds
40.34% Other Institutional Investors
26.14% Public Companies and
Individual Investors